===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Amendment No. 3
Under the Securities Exchange Act of 1934
ARIAD PHARMACEUTICALS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.001 PAR VALUE
---------------------------------------------------------------------------
(Title of Class of Securities)
04033A 10 0
-----------------
(CUSIP Number)
December 31, 1999
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ x ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
===========================================================================
Page 1 of 8
Exhibit Index is located at page 7
<PAGE> 2
CUSIP No. 04033A 10 0
---------------------------------------------------------------------------
1) Name of Reporting Person and its Aventis Pharmaceuticals Inc.
I.R.S. Identification Number 44-0565557
---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
---------------------------------------------------------------------------
3) SEC Use Only
---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
---------------------------------------------------------------------------
5) Sole Voting Power 0
Number of ____________________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 0
Person With ____________________________________________________________
8) Shared Dispositive Power 0
---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 0
by Each Reporting Person
---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
---------------------------------------------------------------------------
11) Percent of Class Represented 0%
by Amount in Row (9)
---------------------------------------------------------------------------
12) Type of Reporting Person CO
---------------------------------------------------------------------------
<PAGE> 3
CUSIP No. 04033A 10 0 13G
---------------------------------------------------------------------------
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
---------------------------------------------------------------------------
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x ]
---------------------------------------------------------------------------
3) SEC Use Only
---------------------------------------------------------------------------
4) Citizenship or Place of Organization Delaware
---------------------------------------------------------------------------
5) Sole Voting Power 0
Number of ____________________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 0
Person With ____________________________________________________________
8) Shared Dispositive Power 0
---------------------------------------------------------------------------
9) Aggregate Amount Beneficially Owned 0
by Each Reporting Person
---------------------------------------------------------------------------
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
---------------------------------------------------------------------------
11) Percent of Class Represented 0%
by Amount in Row (9)
---------------------------------------------------------------------------
12) Type of Reporting Person CO
---------------------------------------------------------------------------
<PAGE> 4
CUSIP No. 04033A 10 0 13G
This Amendment No. 3 to the Statement on Schedule 13G of Aventis
Pharmaceuticals Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware
corporation, is filed solely to reflect the disposition of all of the shares of
Ariad Pharmaceuticals, Inc. The following items of the Statement on Schedule 13G
are hereby amended to read as follows:
ITEM 4. OWNERSHIP
------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
As Of 12/31/99 0 Shares of Series B Convertible Preferred
Stock. On 12/31/99 3,004,436 Shares of Series B
Convertible Preferred Stock were surrendered to Issuer.
(b): PERCENT OF CLASS:
0%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the 0
disposition of:
(iv) Shared power to dispose or to direct the 0
disposition of:
<PAGE> 5
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
June 5, 2000
---------------------------------
(Date)
HMR PHARMA, INC.
/s/ Joan A. Hanlon
---------------------------------
(Signature)
Joan A. Hanlon
Vice President and Treasurer
---------------------------------
(Name/Title)
<PAGE> 6
CUSIP No. 04033A 10 0 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
June 5, 2000
---------------------------------
(Date)
Aventis Pharmaceuticals INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 7
CUSIP No. 04033A 10 0 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
----------- ------------ ---------
99.A Agreement to File Jointly dated June 8
5, 2000, by and between Aventis
Pharmaceuticals Inc. and HMR Pharma, Inc.
<PAGE> 8
CUSIP No. 04033A 10 0 13G
EXHIBIT 99.A
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G is filed on behalf of each of us.
AVENTIS PHARMACEUTICALS INC.
Date: June 5, 2000 By: /s/ Rebecca R. Tilden
--------------------------
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
Date: June 5, 2000 By: /s/ Joan A. Hanlon
--------------------------
Joan A. Hanlon
Vice President and Treasurer
